ProKidney Corp. reported mixed data from its Phase II REGEN-007 trial evaluating rilparencel, a cell therapy for chronic kidney disease (CKD) in diabetic patients. In the two-dose cohort, rilparencel slowed annual kidney function decline by 78%, a statistically significant and clinically meaningful result. The single-dose cohort saw a 50% improvement that was not statistically significant. The therapy consists of autologous progenitor cells injected into diseased kidneys to promote tissue repair. No serious adverse events were noted. ProKidney plans to meet with the FDA to seek acceptance of eGFR slope as a surrogate endpoint in its ongoing Phase III PROACT 1 study, which mirrors the more successful dosing regimen.